Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Hidehito Horinouchi on X: S1801: Neo- vs. adjuvant pembrolizumab for stage III-IV melanoma by @DrSapnaPatel. Striking EFS benefits by neoadjuvant! Simple but highly important clinical question. Expect that it is not limited

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Cancers, Free Full-Text

Neoadjuvant immunotherapy improves outlook in

Schematic overview of the concept of adjuvant melanoma therapy and its

Neoadjuvant pembrolizumab administered before surgery improves outcomes of melanoma patients - ecancer

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA

Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma☆ - Annals of Oncology

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease

VisualAbstract: Adjuvant pembrolizumab does not reduce health-related quality of life in patients with stage III melanoma